Number relapsed‐recurred · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication probably leads to lower number relapsed‐recurred compared with placebo (moderate certainty).
1 finding from 1 review
Suicide‐related behaviour · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in suicide‐related behaviours compared with placebo (low certainty).
1 finding from 1 review
Total number of drop‐outs · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in drop‐outs compared with placebo (moderate certainty).
1 finding from 1 review
Severity of depression at the end of treatment · clinical diagnosis of depression
1 finding from 1 review
Adverse events ( · clinical diagnosis of depression
1 finding from 1 review
Physical quality of life · clinical diagnosis of depression
1 finding from 1 review
Quality of life (emotional) · clinical diagnosis of depression
1 finding from 1 review
Recurrence · older people in remission from depression
Antidepressant medication may leads to lower recurrence at 12 months compared with placebo at 12 months' follow‐up (low certainty).
1 finding from 1 review
Overall drop‐out rates (excluding deaths) at 12 months · older people in remission from depression
Antidepressant medication showed no clear difference in overall drop‐out rates (excluding deaths) at 12 months compared with placebo at 12 months' follow‐up (low certainty).
1 finding from 1 review
Global Efficacy Questionnaire (questions 1 & 2) (Questions assessing improvement attributed to medication compared to having no treatment at all) · people with antidepressant‐induced sexual dysfunction
Sildenafil probably leads to higher global Efficacy Questionnaire (questions 1 & 2) (Questions assessing… compared with placebo (moderate certainty).
1 finding from 1 review
Non‐adherence to medication · adults
Pharmacy‐based management (pharmacist with or without wider team) leads to lower non‐adherence to medication compared with treatment (high certainty).
1 finding from 1 review
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Diabetes · Adults with mental disorders in low‐ and middle‐income countries
Atypical showed no clear difference in diabetes (ADA criteria) (6 weeks) compared with typical antipsychotic medications (low certainty).
1 finding from 1 review
Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Atypical showed no clear difference in drop‐outs (6 to 54 weeks) compared with typical antipsychotic medications (low certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Objective assessment of efficacy at end of treatment (6 months) ‐ rAFS scores · depression in adults
Behavioural activation probably leads to higher treatment efficacy up to 6 months (16 weeks) compared with medication (moderate certainty).
1 finding from 1 review
treatment acceptabilityup to 6 months (12‐16 weeks) · depression in adults
Behavioural activation showed no clear difference in treatment acceptabilityup to 6 months (12‐16 weeks) compared with medication (moderate certainty).
1 finding from 1 review
depression symptoms(continuous) up to 6 months (12 weeks) · depression in adults
1 finding from 1 review
adverse events(16 weeks) · depression in adults
1 finding from 1 review